$33.99
2.50% day before yesterday
Nasdaq, Nov 21, 10:00 pm CET
ISIN
US45166A1025
Symbol
IDYA

IDEAYA Biosciences Inc Stock price

$33.99
+4.79 16.40% 1M
+14.84 77.49% 6M
+8.29 32.26% YTD
+7.39 27.78% 1Y
+16.51 94.45% 3Y
+21.33 168.48% 5Y
+22.80 203.75% 10Y
+22.80 203.75% 20Y
Nasdaq, Closing price Fri, Nov 21 2025
+0.83 2.50%
ISIN
US45166A1025
Symbol
IDYA
Industry

Key metrics

Basic
Market capitalization
$3.0b
Enterprise Value
$2.2b
Net debt
positive
Cash
$786.9m
Shares outstanding
87.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
13.9 | 223.8
EV/Sales
10.2 | 164.7
EV/FCF
negative
P/B
2.7
Financial Health
Equity Ratio
94.2%
Return on Equity
-25.9%
ROCE
-18.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$214.8m | $13.3m
EBITDA
$-206.5m | $-294.1m
EBIT
$-209.1m | $-319.1m
Net Income
$-160.3m | $-278.4m
Free Cash Flow
$-105.4m
Growth (TTM | estimate)
Revenue
5,380.4% | 90.2%
EBITDA
7.1% | 9.4%
EBIT
7.0% | 2.4%
Net Income
10.1% | -1.4%
Free Cash Flow
31.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-96.1% | -2,209.2%
EBIT
-97.3%
Net
-74.6% | -2,091.1%
Free Cash Flow
-49.1%
More
EPS
$-1.8
FCF per Share
$-1.2
Short interest
10.6%
Employees
131
Rev per Employee
$50.0k
Show more

Is IDEAYA Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,049 stocks worldwide.

IDEAYA Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a IDEAYA Biosciences Inc forecast:

22x Buy
88%
3x Hold
12%

Analyst Opinions

25 Analysts have issued a IDEAYA Biosciences Inc forecast:

Buy
88%
Hold
12%

Financial data from IDEAYA Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
215 215
5,380% 5,380%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 56 56
59% 59%
26%
- Research and Development Expense 294 294
52% 52%
137%
-207 -207
7% 7%
-96%
- Depreciation and Amortization 2.55 2.55
5% 5%
1%
EBIT (Operating Income) EBIT -209 -209
7% 7%
-97%
Net Profit -160 -160
10% 10%
-75%

In millions USD.

Don't miss a Thing! We will send you all news about IDEAYA Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IDEAYA Biosciences Inc Stock News

Neutral
Seeking Alpha
17 days ago
IDEAYA Biosciences, Inc. ( IDYA ) Citi's 2025 SMID Cap Biopharma Call Series November 6, 2025 12:00 PM EST Company Participants Yujiro Hata - Founder, President, CEO & Director Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Citigroup Inc., Research Division All right. Great. Hopefully, everyone is connected.
Neutral
PRNewsWire
19 days ago
Phase 2/3 trial (OptimUM-02) of the darovasertib/crizotinib combination in 1L HLA*A2-negative metastatic uveal melanoma (mUM) to report median PFS data by year-end 2025 to 1Q 2026; on track to complete enrollment by year-end 21.1 month median OS and 7.0 month median PFS reported from single-arm Phase 2 trial (OptimUM-01) evaluating the darovasertib/crizotinib combination in 1L mUM Phase 1 data ...
Neutral
PRNewsWire
23 days ago
SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on October 30, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 73,500 shares of the Com...
More IDEAYA Biosciences Inc News

Company Profile

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Yujiro Hata
Employees 131
Founded 2015
Website www.ideayabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today